ASTRIA THERAPEUTICS INC (ATXS) Stock News

NASDAQ:ATXS - Nasdaq - US04635X1028 - Common Stock - Currency: USD

5.97 -0.27 (-4.33%)

After market: 5.97 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ATXS Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit

18 days ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit

a month ago - By: Benzinga - Mentions: PRE CPHI TLSA HCTI ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

a month ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

a month ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

2 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Astria Therapeutics

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

2 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop

2 months ago - By: Astria Therapeutics

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

2 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

3 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

3 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

5 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

5 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

5 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

6 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

6 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

6 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

6 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Benzinga - Mentions: AVGR KALV ATNF ANEB ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

8 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

8 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

9 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)